Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 70/100

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

Key Takeaway: SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2026 on August 3, 2026. The report will be followed by a conference call at 1:30 PM PT. Investors can access the call via registration or through a live webcast on the company's website.
Price reaction · baseline $17.12 (2026-07-20 close) · hit after-hours · clean, no other SIBN news in the window
day 0 close
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in procedural solutions for compromised bone.
  • The company has a strong track record with over 150,000 procedures performed.
  • There is significant clinical evidence supporting SI-BONE's technologies.

Full Press Release Details

SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
Investors interested in listening to the conference call may do so by registering at this link:https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the “Investors” section of the company’s website at:www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 185 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visitwww.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved

Contact

Frequently Asked Questions

When will SI-BONE report its Q2 2026 financial results?

SI-BONE will report its Q2 2026 financial results on August 3, 2026.

What time is the SI-BONE conference call?

The conference call will begin at 1:30 PM Pacific Time.

How can investors access the conference call?

Investors can access the call by registering online or via a live webcast.

What is SI-BONE known for?

SI-BONE is a leader in developing solutions for compromised bone.

Last updated: Jul 20, 2026